{
    "clinical_study": {
        "@rank": "95787", 
        "arm_group": [
            {
                "arm_group_label": "Arm1", 
                "arm_group_type": "Experimental", 
                "description": "1st cycle Palonosetron, 2nd cycle Granisetron"
            }, 
            {
                "arm_group_label": "Arm2", 
                "arm_group_type": "Experimental", 
                "description": "1st cycle Granisetron, 2nd cycle Palonosetron"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the efficacy and safety of palonosetron in preventing the acute and\n      delayed emesis induced by 3-day highly emetogenic chemotherapy. A double-blind, crossover\n      design is used and granisetron is the positive control."
        }, 
        "brief_title": "The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with malignant tumors who can receive 3-day chemotherapy regimens\n             defined by the protocol;\n\n          -  The two-cycle sequential chemotherapy must be the same in drugs, dosage, sequence and\n             routes of administration;\n\n          -  Patients are prohibited from any other chemotherapy drugs during the study, as well\n             as other antiemesis, sedative and psychotropic drugs within 5 days after\n             chemotherapy;\n\n          -  Life expectancy \u2265 3 months;\n\n          -  Adequate hematologic function;\n\n          -  Adequate hepatic function;\n\n          -  Adequate renal function;\n\n          -  At least 2 weeks away from the last chemotherapy;\n\n          -  Patients signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women;\n\n          -  History of anticipatory vomiting;\n\n          -  Radiation therapy on the abdomen or pelvis within one week prior to study entry;\n\n          -  Concomitant use of other drugs which may affect the antiemetic effects (such as\n             omeprazole, amifostine, etc.);\n\n          -  Patients with gastrointestinal obstruction;\n\n          -  Patients with severe heart disease, liver or renal disease, or metabolism disorders;\n\n          -  Patients with epilepsy or using sedative or psychotropic drugs;\n\n          -  Patients with diabetes or with contraindication for corticosteroids;\n\n          -  Patients who received antiemetic drugs or experienced nausea or vomiting within 24\n             hours prior to study entry;\n\n          -  Patients with brain metastasis or intracranial hypertension;\n\n          -  Hypersensitivity to 5-HT3 receptor antagonist;\n\n          -  Patients with active infection;\n\n          -  Other conditions that the investigator considered as unsuitable for chemotherapy;\n\n          -  Subjects participating in other clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909856", 
            "org_study_id": "sim-palonosetron"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm1", 
                    "Arm2"
                ], 
                "description": "Palonosetron 0.25mg d1,d3", 
                "intervention_name": "Palonosetron", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm1", 
                    "Arm2"
                ], 
                "description": "Granisetron 3mg d1-3", 
                "intervention_name": "Granisetron", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm1", 
                    "Arm2"
                ], 
                "description": "Dexamethasone 10mg d1-3", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm1", 
                    "Arm2"
                ], 
                "description": "3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Granisetron", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Emetics", 
                "Palonosetron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430030"
                }, 
                "name": "Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology"
            }, 
            "investigator": {
                "last_name": "Shiying Yu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy", 
        "overall_contact": {
            "last_name": "Shiying Yu, MD", 
            "phone": "86-027-61319612"
        }, 
        "overall_official": {
            "affiliation": "Huazhong University of Science and Technology", 
            "last_name": "Shiying Yu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete Response(CR) within 24-120 hours after chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "24-120 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "CR within 0-120 hours after chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours"
            }, 
            {
                "measure": "CR within 0-24 hours after chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours"
            }, 
            {
                "measure": "Incidence of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }
        ], 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}